Sun Pharma to acquire U.S. firm Organon in $11.75 billion deal

Sun Pharmaceutical Industries Ltd has announced that it has entered into a definitive statement nether which it volition get each outstanding shares of Organon for $14.00 per stock successful an all‑cash transaction with an endeavor valuation of $11.75 billion.

Organon is simply a planetary healthcare institution formed done a spinoff from Merck, known arsenic MSD extracurricular of the United States and Canada, successful 2021.